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Anaplastic thyroid carcinoma (ATC) is one of the most deadly cancers. With intensive multimodalities of treatment, the survival
remains low. ATC is not sensitive to 131I therapy due to loss of sodium iodide symporter (NIS) gene expression. We have previously
generated a stable human NIS-expressing ATC cell line, ARO, and the ability of iodide accumulation was restored. To make
NIS-mediated gene therapy more applicable, this study aimed to establish a lentiviral system for transferring hNIS gene to cells
a n dt oe v a l u a t et h ee ﬃcacy of in vitro and in vivo radioiodide accumulation for imaging and therapy. Lentivirus containing
hNIS cDNA were produced to transduce ARO cells which do not concentrate iodide. Gene expression, cell function, radioiodide
imaging and treatment were evaluated in vitro and in vivo. Results showed that the transduced cells were restored to express
hNIS and accumulated higher amount of radioiodide than parental cells. Therapeutic dose of 131Ie ﬀectively inhibited the tumor
growth derived from transduced cells as compared to saline-treated mice. Our results suggest that the lentiviral system eﬃciently
transferred and expressed hNIS gene in ATC cells. The transduced cells showed a promising result of tumor imaging and therapy.
1.Introduction
Anaplastic thyroid cancer (ATC) is rare and represents less
than 2% of all thyroid cancer [1]. Nevertheless, it is one of
the most deadly human cancers which causes more than half
of the deaths attributed to thyroid cancer [2]. Currently,
treatment for ATC is mainly surgery combined with chem-
otherapy and radiotherapy. Although intensive multimodal-
ities of treatment shows improved local control, the overall
survival remains low [3]. Other strategy for treating ATC
including new drugs is urgently underway.
ATC does not concentrate iodide due to the loss of ex-
pression of sodium iodide symporter (NIS) gene. NIS is a
membrane protein with 13 putative transmembrane domain
[4]. This symporter is driven by low internal sodium con-
centration and symports 2 sodium ions for every iodide ion
into cells. For thyroid cells, NIS mediated iodide transport is2 Journal of Oncology
the ﬁrst step of triiodothyronine (T3) and thyroxine (T4)
synthesis [5]. Function of iodide transport of NIS has been
used in radioiodide imaging and therapy. For well-differen-
tiated thyroid cancer, 131I ablation and whole-body scintilla-
tion scan after thyroidectomy is currently the most frequent
treatment protocol [6]. After NIS gene had been cloned,
several investigators used it as an imaging and therapeutic
tool in gene therapy. By introducing NIS gene into variety
of cancer cells which do not concentrate iodide, it showed a
promising therapeutic eﬀect after administrating therapeutic
isotopes [7]. By means of γ-camera or positron emission
tomography with radioiodide, the accumulation of tracer
which reﬂects the expression of transferred NIS gene can be
monitored.WehaveshowntheeﬀectivenessofNIS-mediated
radioiodide therapy on tumors derived from ATC cell line,
ARO [8]. However, the model in previous study was stable
cells established by transient transfection and clonal expan-
sion.
Virus-mediated gene delivery has been used for decades
in biological research. Retrovirus has been the mainstay of
currentgenetherapyapproachduetoitshigheﬃciencyofin-
fection and high expression of transferred gene. Long-term
expression of delivered gene attributed to genome integra-
tion is also a useful advantage. However, the use of retrovirus
requires the cells being in an actively dividing status [9]. An-
other type of retrovirus, lentivirus, which infects both divid-
ingandnondividing cellshasemergedaspotentandversatile
vectors for gene transfer [10] .I nt h i ss t u d y ,w ea i m e dt o
establishalentiviralsystemtodeliverNISgeneintoAROcells
and evaluate the eﬃcacy of radioiodide imaging and therapy.
2.MaterialsandMethods
2.1. Cell Culture. 293T (BCRC60019) were obtained from
the Bioresource Collection and Research Center in Taiwan.
The ARO thyroid cancer cell line was kindly provided by Dr.
Chin-Wen Chi (National Yang-Ming University, Taiwan). All
media and tissue culture supplements were obtained from
Gibco-BRL (Invitrogen, Carlsbad, Calif, USA). 293T cells
were grown in minimum essential medium (MEM). ARO
cells were maintained in RPMI-1640 medium. All complete
media were supplemented with 10% fetal bovine serum
(FBS), 2mM L-glutamine, 100U/mL penicillin, and 100μg/
mL streptomycin. Cells were cultured in a humidiﬁed incu-
bator at 37◦C and 5% CO2: 95% air.
2.2. Vector Construction and Virus Production. The hNIS
cDNA cloned in pcDNA3 (FL∗-hNIS/pcDNA3) was kindly
provided by Dr. Sissy Jhiang (Ohio State University). The
CMV promoter linked with hNIS in pcDNA3 vector was
enzymatically removed and then ligated into LentiLox 3.7
vector (pLL3.7) with proper restriction enzyme to create
pLL3.7-hNIS (Figure 1). Lentiviral particles were produced
following the protocol published by Tiscornia et al. with
some modiﬁcation [11]. 6 × 106 293T packaging cells per
100mm tissue culture plate were seeded and cultured in
DMEM supplemented with 10% FBS for 24 hours. Tran-
sient transfection was carried out using Lipofectamine 2000
(Invitrogen, Carlsbad, Calif, USA) following the manual
3’LTR
pUC
Amp CMV
Psi
FLAP
U6
LoxP
CMV
hNIS
LoxP
WRE
pLL3.7-hNIS
5 LTR
Figure 1: Scheme of constructed hNIS-expressing lentiviral vector.
instruction. Plasmid DNA and reagent were mixed and incu-
bated for 20 minutes at room temperature to form the DNA-
Lipofectamine complexes. The mixture was then added to
293T cell culture and incubated overnight. On the next day,
the media were removed and replaced with fresh culture me-
dia containing 1% (w/v) BSA. At 72 hour after transfection,
the viral particle-containing supernatant was harvested in
sterile, capped conical tubes, and centrifuged at 300g for
15 minutes at 4◦C to pellet cell debris. The virus-containing
supernatants(LV-CMV-hNISandLV-CMV-EGFP)werethen
passed through a sterile, 0.45μm low protein-binding, Mil-
lex-HV PVDF ﬁlter (Millipore, Bedford, Mass, USA). The
ﬂowthrough was collected and overlaid on the top of 4mL
20% sucrose solution prepared by PBS in the centrifuging
tubes. Virus concentration was carried out by centrifugation
at 26.000rpm, 4◦C for 1.5hrs. After decanting the super-
natant, the pellet of viral particles was reconstituted by
mixing in the HBSS and stored at −80◦C. The virus titer was
assayed by the QuickTiter Lentivirus Quantitation Kit (Cell
Biolabs, Inc., USA).
2.3. Immunocytochemistry Study. Cells were seeded and al-
l o w e dt og r o wo n2 2m m× 22mm coverslips (Marienfeld,
Lauda-Konigshofen, Germany). After a 24h incubation, cells
were rinsed with PBS for 3 times and then ﬁxed in 4% para-
formaldehyde for 15min at room temperature. After three 5-
min washes by PBS, the cells were permeabilized with 0.1%
Triton X-100 in PBS/CM/BSA (PBS with 0.1mM CaCl2,
1mMMgCl 2, and 0.2% BSA) for 10min. After three 5-min
washes by PBS, the cells were incubated with a 1:100 dilu-
tion of mouse anti-hNIS polyclonal antibody (Chemicon,
Temecula, USA) for 1 hour at room temperature and washed
with PBS. A 1:200 dilution of FITC-conjugated goat anti-
mouse IgG (Santa Cruz Biotechnology, Santa Cruz, USA)
was then added to cells and incubated for 1 hour at room
temperature and followed by PBS wash. Nuclei were stained
using Bisbenzimide H33342 for 30 minutes at room temper-
ature. After three ﬁnal PBS washes (5min each), the cells
were mounted with mounting solution. Fluorescent images
of cells were observed using a Leica TCS SP5 confocal micro-
scope.Journal of Oncology 3
2.4. Polymerase Chain Reaction (PCR) for Detecting the Inte-
gratedTransgeneandGeneExpression. TransducedAROcells
and parental cells were expanded in culture, and total ge-
nomic DNA was isolated using the DNeasy kit (Qiagen, Va-
lencia, Calif, USA) following the manufacturer’s instruction.
Integrated hNIS DNA was ampliﬁed by PCR with designed
forward primer, 5 -TCAGCACAGCATCCACCAG-3  and
reverse primer, 5 -GGGCACCGTAATAGAGATAG-3 .T h e
PCR protocol was set as follow: 94◦C for 4min, 94◦C
for 30s, 56◦Cf o r3 0 s ,a n d7 2 ◦C for 30s, with repeating
reaction cycle for 30 times. For the detection of RNA ex-
pression, cells were lysed, and total RNA was isolated using
RNeasy mini kit (Qiagen, Valencia, Calif, USA). cDNA syn-
thesis was carried out using MMLV reverse transcriptase
(Epicentre Biotechnologies, Madison, Wlis, USA) accord-
ing to the manufacturer’s instruction. In the subsequent
PCR reaction, the primers previously described were used
to amplify the hNIS gene. As internal controls, primer that
hybridize to a segment of the β-actin cDNA were included
in the same reaction mixture (β-actin forward primer:
5 -TCAAGATCATTGCTCCTCCTGAGC-3 ; β-actin reverse
primer: 5 -GGGCACCGTAATAGAGATAG-3 ). The anneal-
ing temperature for β-actin was 54◦C.
2.5. In Vitro 125IU p t a k e .In vitro cellular 125Iu p t a k ew a s
measured according to Weiss et al. [12] with little modiﬁca-
tion. 5 × 105 cells per well were seeded in 12-well plates the
day before experiment. After rinsed with Hanks’ balanced
salt solution (HBSS), cells were incubated with 0.5mL HBSS
containing10μMofNaIand3700Bqof 125Iat37 ◦C.At5,10,
20, 30, and 60 minute, cells were washed quickly with 1mL
of iodide-free icecold HBSS. Cells were then detached by
trypsin, and all cells were collected and resuspended in 1mL
HBSS in counting tubes. The radioactivity was measured
using a Cobra II autogamma counter (Packard instrument,
Conn, USA) following the manual procedure.
2.6. In Vivo 124I Imaging and Quantitative Image Analysis.
F o ri nv i v oi m a g i n gs t u d y ,1× 107 ARO parental cells and
cells transduced with LV-CMV-hNIS were subcutaneously
injected into the right ﬂank of shoulder of male NOD/SCID
mice.Afterthetumorsreachedto8mmindiameter,themice
were injected intravenously with 124I (1.85MBq). After One
hour,micewereanesthetizedwith2%isoﬂurane(ForaneAb-
bott Laboratories, Queenboroug, Kent, England) and 98%
oxygen mixture and secured on the imaging table in the
prone position. Static images were obtained using the micro-
PET R4 scanner (Siemens Preclinical Solutions, Knoxville,
Tenn, USA) for 30min. Fully 3-dimensional list mode data
were collected for 30min using an energy window of 350–
750keV and a timing window of 6ns. For maximum sen-
sitivity, coincidence data were rebinned into 3-dimensional
sinogramsusingthefullaxialacceptanceangleofthescanner
(max. ring diﬀerence = 31). To preserve axial resolution,
high sampling of the polar angle was used (span = 3). The
resulting 3D sinograms were then rebinned into 2D sino-
grams using Fourier rebinning (FORE) and reconstructed
with 2-dimensional ﬁltered back projection (FBP) using a
ramp ﬁlter with cutoﬀ at Nyquist. The image matrix size
was 256 × 256. Data manipulation was carried out via the
MicroPET Manager software provided by the manufacturer.
No attenuation correction was performed. The images were
i n t e r p r e t e dq u a l i t a t i v e l y .A l li m a g e sw e r ee x p r e s s e di nt h e
ordinary rainbow color scale with standard visual spectrum
installed in the computer of the microPET system.
2.7. In Vivo 131I Therapy. T u m o r sg r o w no nm i c ew e r ea s -
sessed for the eﬀect of 131I therapy. Two weeks after cell inoc-
ulation, mice bearing tumors were intraperitoneally injected
with55.5MBq(1.5mCi) 131Iorsamevolumeofnormal.The
tumor size was measured twice a week after 131It r e a t m e n t .
Tumor volume was measured by caliper and calculated using
the equation VT (mm3) = L × W × D × 0.52, where VT is
the estimated tumor volume, and L, W,a n dD are the length
(mm), width (mm), and depth (mm) of the tumor, respec-
tively.
3. Result
3.1. Immunocytochemistry Study. To evaluate the hNIS ex-
pressionintransducedAROcells,weperformedimmunoﬂu-
orescent staining. Using mouse anti-hNIS primary antibody
coupled with FITC-conjugated goat anti mouse IgG, ﬂuores-
cence emitted from FITC ﬂuorophore was shown localized
on the cellular surface of transduced cells, compared with
the location of cell nuclei stained by H33342 (Figure 2(b)).
ARO parental cells treated with the same staining procedure
showed no FITC-related ﬂuorescent signal, indicating no or
lowexpressionofhNISinthesecells(Figure 2(a)).Thisresult
indicates the eﬃcient transfer and subsequent expression of
hNIS by lentiviral transduction.
3.2. PCR for Detecting the Integrated Viral Vector and Gene
Expression. To verify the lentiviral integration of exogenous
hNIS construct in transduced ARO cells, we have previ-
ously performed PCR with designed primers to detect the
integrated construct in genomic DNA isolated from ARO
parental cells and transduced cells [13]. In Figure 3,t r a n s -
duced cells showed apparent exogenous hNIS PCR amplicon
with expected size (lane 5) while parental cells had no detect-
ed band (lane 4). RT-PCR was also performed to detect RNA
expressioninparentalandtransducedcells.Afterperforming
reverse transcription and subsequent PCR, expression of
exogenous hNIS was observed (lane 2) and parental cells
showed no detected expression (lane 1).
3.3. In Vitro Radioiodide Uptake. To evaluate the function of
iodide uptake of transduced cells, we have previously per-
formed the sequential in vitro 125Iu p t a k ee x p e r i m e n t[ 13].
ARO parental cell or cells transduced with LV-CMV-hNIS
or LV-CMV-hNIS were incubated in 125I-containing HBSS
followed by γ counting the radioactivity within cells at
diﬀerent time points. As shown in Figure 4, cells transduced
with LV-CMV-hNIS accumulated 125I rapidly in 10 minutes,
and the radioactivity reached to the plateau at 20 minutes
from beginning. ARO parental cells and cells transduced
with LV-CMV-EGFP showed a minimal 125I uptake and no4 Journal of Oncology
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Figure 2: Immunoﬂuorescence of ARO cells transduced with LV-CMV-hNIS. Cells were immunostained with mouse anti-hNIS antibody
and FITC-conjugated goat anti-mouse 2nd antibody. ARO parental cells showed no detection of hNIS expression (a). Nuclei was stained
by H33342 and shown in blue. hNIS protein expression (green) on the cellular membrane of transduced ARO cells was clearly detected by
confocal ﬂuorescent microscopy (b).
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Figure 3: Detection of integrated hNIS sequence and RNA expres-
sionLentiviralintegrationofhNISconstructwasconﬁrmedbyPCR
amplifying the speciﬁc DNA fragment in genomic DNA. Lane 4
and 5 represent the result of amplifying integrated hNIS fragment
from isolated genomic DNA of parental and transduced cells,
respectively. As assayed by RT-PCR, lane 1 and 2 represent the RNA
expression of exogenous hNIS of parental and transduced cells,
respectively. Same reaction was also carried out for detecting RNA
expression of β-actin and was shown in all lanes. Lane 3 represents
thePCRresultwithhNIS-containingplasmidasthetemplatewhich
was a control.
higher accumulation as the time increased. At 20 minute, the
index of accumulated 125I in cells transduced with LV-CMV-
hNIS was ∼7 times higher than that of parental cells or cells
transduced with LV-CMV-EGFP. This result demonstrates
the lentiviral-transferred hNIS, exhibits its original function,
and consequently restores the ability of iodide uptake of
anaplastic thyroid cancer cells.
3.4. In Vivo Radioiodide Imaging by MicroPET. In order to
know whether ARO-transduced cells retain the expression of
hNIS and the function of iodide uptake, we established the
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Figure 4: Time course of 125I uptake of ARO cells. ARO parental
cells, cells transduced with LV-CMV-EGFP or LV-CMV-hNIS were
measured for accumulation of 125Ia td i ﬀerent time point. ARO cells
transduced with LV-CMV-hNIS showed more eﬀective accumula-
tion of 125I than parental cells or cells transduced with LV-EGFP.
Values are the mean ± standard deviation (n = 3).
tumors derived from ARO parental and transduced cells on
NOD/SCID mice. 1 hour after intravenously injecting 124I,
mice were imaged using microPET scanner. Static image of
mice bearing tumor derived from ARO parental cells (left)
and transduced cells (right) was acquired for 30 minutes and
is shown in Figure 5. Tumor derived from transduced cells
showed more eﬃcient accumulation of 124I while compared
to tumor derived from parental cells. This result indicates
transduced cells retain not only the expression of transferred
hNIS but the ability to accumulate iodide.Journal of Oncology 5
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Figure 5: In vivo 124I MicroPET imaging ARO parental cells and
cells transduced with LV-CMV-hNIS were subcutaneously implant-
ed into mice shoulder and allowed to form the tumors. When tu-
mors reached 8mm in size, images were taken for 30min at 60min
after administration of 1.85 MBq (50uCi) of 124I. Images show that
tumor derived from transduced ARO cells accumulates 124Im o r e
eﬃciently than tumor derived from ARO cells.
3.5. In Vivo 131I Therapy. To know the eﬃcacy of 131I therapy
of hNIS-expressing tumor, mice bearing tumors were treated
with 55.5 MBq (1.5mCi) of 131I or saline. Result shows that
tumor growth was eﬀectively inhibited by treating with 131I,
as compared to tumors treated with saline (Figure 6). This
data as well as result of in vivo imaging indicate tumor
derived from transduced cells that retain the expression and
function of hNIS even in the in vivo environment.
4. Discussion
Using lentiviral vector, we have successfully transduced ATC
cells with NIS gene which was markedly expressed and well
functioning in the transduced cells. Tumors established by
transduced cells retained high expression of hNIS which
enable tumors to be well treated by 131I and monitored with
radioiodide imaging. Our previous data showed that stable
cells oﬀered a good model to test the feasibility of NIS-me-
diated gene therapy. However, gene delivery by viral trans-
duction is more applicable in vivo. Lentivitral gene transfer
was intensively used due to its advantages, including stable
integration of transgene, capability of transducing dividing
and nondividing cells and long-term transgene expression.
Kim et al. showed eﬀective long-term monitoring and radio-
nuclide therapy of colon cancer cells in living organism by
using a lentiviral vector system carrying hNIS controlled by
UbC promoter [14]. Dingli et al. also used lentivectors to
target and express hNIS in myeloma cells for 131I therapy.
Results showed that tumor xenografts treated with 131I
were completely eradicated without recurrence [15]. Reports
above indicate the potential of lentiviral vector combined
withNISgenetherapyoncancer.Ourdataistheﬁrstdemon-
stration of lentiviral NIS-mediated gene therapy on anaplas-
tic thyroid cancer.
Iodide is retained within thyroid gland for a period of
timeduetomultipleprocessesofthyroidhormonesynthesis.
Zuckier et al. reported that 131I concentrated within thyroid
gland continued to increase at 19h after administration into
mice according to a biodistribution experiment [16]. Same
resultwasnotedbyourpreviousstudy[8].ByanalyzingROIs
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Figure 6: In vivo 131I therapy of ARO tumors mice bearing tumors
derived from transduced ARO cells were intraperitoneally injected
with 55.5 MBq (1.5 mCi) of 131I or same volume of saline. Tumor
growth was recorded twice a week. The group treated with 131I
(n = 5) showed eﬃcient inhibition of tumor growth while the
group treated with saline (n = 3) showed rapid growth of tumors.
of serial images acquired using a γ-camera, radioactivity in
thyroid gland reached the peak around 20 hours after 131I
injection. Similar experiment also revealed that within 5
hours from injection, equal level of 131I accumulation was
noted in thyroid gland and in tumors derived from ARO
stable cells, while only 1/3 of 131I activity was measured
in tumors derived from ARO parental cells. Radioactivity
within tumors decreased after 5 hours in contrast to increase
in thyroid gland. Results showed that without further steps
of T3 and T4 synthesis, iodide pumped into cell by NIS is
rapidly eﬄuxed. This drawback greatly reduces the feasibility
of NIS in gene therapy.
To solve the problem of short retention of radioiodide,
Huang et al. coexpressed NIS and TPO in nonsmall cell lung
cancer which increased retention time of radioiodide within
cells as compared to cells expressing NIS alone [17]. Furuya
etal.deliveredTTF-1(thyroidtranscriptionfactor1)toNIS-
transfected cells. TTF-1 is the thyroid speciﬁc transcription
factor and able to turn on the expression of downstream
t h y r o i ds p e c i ﬁ cg e n e ss u c ha sT g ,T P O ,a n dN I S[ 18–20].
However, delivery of more than one gene into cells greatly
increases the diﬃculty. Despite the short retention of radi-
oiodine within transduced cells, the growth of tumors still
showed signiﬁcant inhibition in this study and our previous
data [8] .H i gh l ye x p r e s s e dN I Sa l o n ewi t hs u ﬃcient but non-
lethaldoseofadministered 131Imaycompensatetheproblem
of short retention of radioiodide.
Recently, a comprehensive DNA sequence proﬁling anal-
ysis has pointed that ARO cells are highly identical with
HT-29, a colon cancer cell line [21]. However, several stud-
ies demonstrated that with treatment of certain agents, ex-
pression of thyroid speciﬁc genes could be restored in ARO
cells. Landriscina et al. showed that the reverse transcriptase
inhibitors recovered the thyrotropin signaling and iodide
uptake ability [22]. Upon treatment of histone deacetylase6 Journal of Oncology
(HDAC) inhibitors such as depsipeptide and trichostatin A
(TSA), thyroid-speciﬁc gene expression and accumulation
of radioiodide through the iodination of generic cellular
proteins were detected in ARO cells [23]. ARO cells were also
shown to express thyroid stimulatory hormone receptor
(TSHR), and the population which expressed TSHR in-
creased following treatment of TSH in a dose-dependent
manner [24]. Despite the published results which demon-
strated that ARO cells retain the function and speciﬁc gene
expressionrelatedtothyroidcells,moreevidencesareneeded
to clarify the identity of ARO cells.
Lentiviral gene transfer is considered as a promising ap-
proach to cancer gene therapy. Cancer-speciﬁc targeting is
one of key point in the in vivo gene therapy. In this study,
CMV promoter which has been reported as one of the
strongest promoters in vitro was used in our transduction
system. However, in the in vivo system, silence of gene gov-
erned by CMV was noted within a few weeks in several
organs [25, 26]. In addition, CMV is a universal promoter
which cannot be used to speciﬁcally activate downstream
gene expression in speciﬁc cell type. Therefore, a promoter
which speciﬁcally target ATC is urgently needed. We pre-
viously demonstrated that using a hepatoma chimeric pro-
moter (EIIA enhancer combined with α-fetoprotein pro-
moter) to target hepatocarcinoma cells (HCCs) resulted in
speciﬁcally turning on the hNIS transgene in HCC, but not
in non-HCC [13]. Thyroglobulin promoter was reported to
target thyroid cancer. With transfer and speciﬁc expression
of TK gene driven by the Tg promoter in thyroid cancer
cells, result showed marked killing ability in the presence
of GCV, little in vivo toxicity, and should be useful in the
future for treating thyroid Tg-producing cancers [27]. ATC
is known as a poorly diﬀerentiated thyroid carcinoma with
reduced or silenced expression of several thyroid-speciﬁc
genes, including NIS and Tg. Therefore, to design an ATC-
speciﬁc lentiviral targeting system, promoter of Tg gene can
not work for this purpose. Our future work will focus on
searching for a suitable promoter for ATC in our lentivirus-
mediated NIS radiogene therapy.
5. Conclusion
We have established a lentiviral system for delivering hNIS to
AROcell.Thetransducedcellsshowedhighexpressionofthe
transgene and restored the ability of radioiodide accumu-
lation. Tumors derived from the transduced cells showed
eﬀective in vivo imaging and therapy. This study oﬀers a
promising, applicable way to treat ATC.
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